Clozapine
Clozaril · Versacloz (oral suspension) · FazaClo (ODT)
Indications for Clozapine
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Treatment-resistant schizophrenia | Adults (failed ≥2 adequate antipsychotic trials) | Monotherapy or adjunctive | FDA Approved |
| Reduction in risk of recurrent suicidal behaviour | Adults with schizophrenia or schizoaffective disorder judged at chronic risk | Monotherapy or adjunctive | FDA Approved |
Clozapine remains the gold-standard treatment for schizophrenia that fails to respond adequately to at least two other antipsychotic agents at adequate doses and duration. It is the only antipsychotic with demonstrated superiority in treatment-resistant disease, established in the landmark Kane et al. (1988) trial versus chlorpromazine. The InterSePT trial further demonstrated a unique anti-suicidal benefit over olanzapine in patients with schizophrenia or schizoaffective disorder at chronic risk for suicidal behaviour.
Psychosis in Parkinson’s disease (evidence quality: moderate): Low-dose clozapine (6.25–50 mg/day) is supported by randomised controlled trial evidence and endorsed by the MDS Evidence-Based Medicine Review. It is the only antipsychotic besides pimavanserin with Level I evidence for PD psychosis.
Treatment-resistant bipolar disorder (evidence quality: low): Case series and small open-label studies support use in refractory mania or mixed episodes, though no RCT data exist.
Tardive dyskinesia management (evidence quality: low): Clozapine has the lowest propensity for tardive dyskinesia of all antipsychotics and may suppress existing TD symptoms when patients are switched from other agents.
As of February 24, 2025, the FDA no longer expects prescribers, pharmacies, or patients to participate in the Clozapine REMS programme or to report ANC results before dispensing. The REMS was formally removed effective June 13, 2025. However, ANC monitoring according to prescribing information frequencies remains strongly recommended. Information about severe neutropenia will remain in the boxed warning.
Dosing for Clozapine
Adult Dosing — Treatment-Resistant Schizophrenia & Suicidality Reduction
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Treatment-resistant schizophrenia — initial titration | 12.5 mg once or twice daily | 300–450 mg/day in divided doses (by end of week 2) | 900 mg/day | Increase by 25–50 mg/day if tolerated; then up to 100 mg increments once or twice weekly Slow titration essential to minimise hypotension, syncope, and seizure risk |
| Suicidality reduction in schizophrenia/schizoaffective disorder | 12.5 mg once or twice daily | 300–450 mg/day in divided doses | 900 mg/day | Continue for at least 2 years (InterSePT trial duration) Most patients also receive adjunctive antidepressants, mood stabilisers, or psychotherapy |
| Restarting after 1 day missed | 40–50% of established dose | Titrate back to previous dose as tolerated | Hypotension and syncope risk recurs after even brief interruption | |
| Restarting after 2 days missed | ~25% of established dose | Titrate back to previous dose | Monitor orthostatic vitals carefully during re-titration | |
| Restarting after >2 days missed | 12.5 mg once or twice daily | Re-titrate (may be faster than initial titration if previously tolerated) | Essentially treat as a new start; ANC must meet baseline thresholds | |
| Planned discontinuation | Taper gradually over 1–2 weeks; monitor for cholinergic rebound (sweating, nausea, vomiting, diarrhoea) and psychotic relapse | |||
CYP Interaction-Based Dose Adjustments
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Co-administration with strong CYP1A2 inhibitor (e.g. fluvoxamine, ciprofloxacin) | Use one-third of the clozapine dose | Adjust based on levels | On discontinuation of inhibitor, increase clozapine dose based on clinical response Fluvoxamine can raise clozapine levels 5–10 fold | |
| Tobacco smoking cessation | Reduce clozapine dose by ~30–50% when stopping smoking | Smoking induces CYP1A2; cessation removes induction and raises levels Nicotine replacement does not affect CYP1A2; it is the polycyclic aromatic hydrocarbons in smoke | ||
| Strong CYP3A4 inducer (e.g. carbamazepine, phenytoin, rifampin) | Concomitant use not recommended; if essential, may need to increase clozapine dose substantially and monitor levels Carbamazepine also carries additive neutropenia risk — avoid if possible | |||
Clozapine is one of the few antipsychotics where plasma-level monitoring has established clinical utility. A trough level of at least 350 ng/mL is associated with optimal response in treatment-resistant schizophrenia. Levels above 600 ng/mL increase seizure risk and toxicity. Draw trough levels at least 12 hours after the last dose, ideally after steady state (~5–7 days at stable dose). TDM is especially valuable when adjusting for smoking status changes, adding/removing CYP inhibitors, assessing non-response, or suspecting non-adherence.
Pharmacology of Clozapine
Mechanism of Action
Clozapine has a uniquely broad receptor-binding profile that distinguishes it from all other antipsychotics. It acts as an antagonist at dopamine D4 receptors (with relatively weak D2 blockade), serotonin 5-HT2A and 5-HT2C receptors, alpha-1 and alpha-2 adrenergic receptors, histamine H1 receptors, and muscarinic M1/M3/M5 receptors. Its low D2 occupancy (typically 40–60% at therapeutic doses, well below the 65–80% threshold for other antipsychotics) is thought to explain its minimal propensity for extrapyramidal symptoms and prolactin elevation. The preferential D4 and serotonergic activity, combined with effects at glutamatergic and GABAergic systems, likely underlies its superior efficacy in treatment-resistant disease, though the precise mechanism remains incompletely understood.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Nearly complete; oral bioavailability 27–70% (highly variable first-pass effect); Tmax ~2.5 h; food does not affect extent of absorption | Large inter-individual variability in plasma levels for the same dose makes therapeutic drug monitoring essential; can be taken with or without food |
| Distribution | Vd = 1.6–7.3 L/kg; protein binding ~97% (primarily to alpha-1-acid glycoprotein); crosses blood–brain barrier | Wide tissue distribution; highly protein-bound, so levels may change with alterations in alpha-1-acid glycoprotein (e.g. inflammation, hepatic disease) |
| Metabolism | Extensive hepatic via CYP1A2 (primary), CYP3A4, CYP2D6; active metabolite norclozapine (N-desmethylclozapine, 20–30% of parent); clozapine N-oxide is the other major metabolite | CYP1A2 dependence makes clozapine levels highly sensitive to smoking (induction) and fluvoxamine/ciprofloxacin (inhibition); CYP2D6 poor metabolisers may require lower doses |
| Elimination | t½ ~12 h (range 9–17 h); ~14 h at steady state; ~50% excreted in urine, ~30% in faeces, almost entirely as metabolites | Twice-daily dosing is standard; steady state reached in approximately 5–7 days; dose reduction may be required in significant renal or hepatic impairment |
Side Effects of Clozapine
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Somnolence / Sedation | up to 46% | Most prominent in early titration; may attenuate over weeks; dose at bedtime if single-dose regimen used |
| Hypersalivation (sialorrhoea) | up to 48% | Paradoxical effect despite anticholinergic properties; worst at night; sublingual atropine drops or hyoscine may help |
| Weight gain (≥7% body weight) | up to 31% | Among the highest of all antipsychotics; mean gain ~4 kg in short-term trials, often more long-term; metformin may be considered adjunctively |
| Dizziness / Vertigo | up to 27% | Related to alpha-1 blockade and orthostatic hypotension; slow titration mitigates risk |
| Tachycardia | up to 25% | Sustained; mean increase 10–15 bpm; not purely reflex; present in all positions; usually benign but must distinguish from myocarditis |
| Constipation | up to 25% | Anticholinergic-mediated; can progress to fatal ileus; proactive bowel regimen recommended for all patients |
| Nausea / Vomiting | up to 17% | Dose-related; usually self-limiting during titration phase |
| Hypotension | up to 13% | Most dangerous during initiation; syncope and cardiac arrest have occurred even at 12.5 mg |
| Fever | up to 13% | Benign transient fever peaks in first 3 weeks; must rule out infection, NMS, and neutropenia |
| Headache | up to 10% | Generally self-limiting |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Tremor | 6% | Generally mild; dose-related |
| Syncope | 6% | Highest risk during initiation; may be fatal; monitor orthostatic vitals |
| Sweating | 6% | Autonomic effect; not typically requiring intervention |
| Dry mouth | 6% | Anticholinergic effect; paradoxically co-exists with hypersalivation in many patients |
| Visual disturbances | 5% | Blurred vision from anticholinergic effects on ciliary muscle |
| Nocturnal enuresis | 2–6% | May respond to desmopressin nasal spray or dose adjustment |
| Hyperglycaemia / New-onset diabetes | ~5% | Highest metabolic risk among antipsychotics alongside olanzapine; monitor fasting glucose and HbA1c |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Severe neutropenia (ANC <500/µL) | ~1% in first 18 weeks | First 6 months; risk declines thereafter | Discontinue immediately; daily ANC monitoring; haematology consultation; do not rechallenge unless benefits clearly outweigh risks |
| Myocarditis | ~1% | Usually first 2 months (median 2–3 weeks) | Discontinue clozapine; obtain troponin, CRP, echocardiogram; cardiology consultation; generally do not rechallenge |
| Cardiomyopathy | Rare | Usually after 8 weeks; can occur at any time | Discontinue; complete cardiac evaluation; generally do not rechallenge |
| Seizures | ~5% cumulative at 1 year | Dose-related; risk increases above 600 mg/day | Reduce dose; add anticonvulsant (valproate preferred; avoid carbamazepine); do not abruptly discontinue clozapine |
| GI hypomotility / Paralytic ileus | Potentially fatal | Any time; higher mortality than agranulocytosis | Proactive bowel regimen for all patients; abdominal imaging if constipation worsens; surgical consultation for obstruction |
| Pulmonary embolism / DVT | Uncommon | Any time | Investigate respiratory distress or leg swelling promptly; standard DVT/PE management |
| Hepatotoxicity | Rare | Any time | Discontinue if hepatitis or symptomatic transaminase elevation occurs; monitor LFTs |
| Neuroleptic malignant syndrome | Very rare | Any time; often with concomitant lithium or other CNS drugs | Immediate discontinuation; intensive supportive care |
Clozapine-induced gastrointestinal hypomotility currently carries a higher mortality rate than agranulocytosis. Up to 80% of clozapine-treated patients show objective evidence of slowed colonic transit. All patients should receive a proactive bowel regimen from initiation, including adequate hydration, dietary fibre, and aperients (e.g. docusate, macrogol). Patients who report no bowel movement for 3 or more days require urgent assessment including abdominal examination and imaging. Avoid concomitant anticholinergic medications whenever possible.
Drug Interactions with Clozapine
Clozapine is extensively metabolised by CYP1A2 (primary), CYP3A4, and CYP2D6. Its heavy reliance on CYP1A2 makes it uniquely sensitive to tobacco smoking (induction) and drugs like fluvoxamine and ciprofloxacin (inhibition). Because clozapine is metabolised by multiple CYP pathways, the risk from any single interaction is partially buffered — but potent CYP1A2 modulation can override this buffering effect dramatically.
Monitoring for Clozapine
- ANC (CBC with differential)Weekly × 6 months; biweekly 6–12 months; monthly after 12 months
RoutineBaseline ANC must be ≥1500/µL (general population) or ≥1000/µL (BEN patients). REMS no longer required as of 2025, but monitoring per PI frequencies remains strongly recommended. Interrupt clozapine if ANC <1000/µL (general) or <500/µL (BEN). - Metabolic PanelBaseline, 12 wk, then annually
RoutineFasting glucose, HbA1c, lipid panel. Clozapine carries the highest metabolic risk alongside olanzapine. Mean fasting glucose increase ~11 mg/dL; diabetes prevalence elevated. - Body Weight & BMIBaseline, monthly × 3 months, then quarterly
Routine≥7% weight gain reported in ~35% of patients. Consider metformin for prevention. - Cardiac Monitoring (troponin, CRP, ECG)Baseline; troponin + CRP weekly × 4 weeks; ECG at baseline
RoutineScreen for myocarditis during first month. Obtain echocardiogram if troponin rises, persistent tachycardia, dyspnoea, or chest pain develop at any point. ~90% of suspected cases are false positives — cardiology confirmation is important before cessation. - Clozapine Trough LevelAfter steady state (~1 week); when dose adjusted; when CYP modulators change
Trigger-basedTarget 350–600 ng/mL. Draw 12 h post-dose. Useful to assess adequacy of response, suspected non-adherence, or toxicity risk. Levels >1000 ng/mL are associated with seizure and coma. - Bowel FunctionEvery visit; proactive assessment
RoutineEnquire about bowel frequency at each visit. Initiate prophylactic laxatives. If no bowel movement for ≥3 days, perform abdominal examination and consider imaging. - Liver Function TestsBaseline; repeat if symptoms arise
Trigger-basedHepatotoxicity can be fatal; transient benign transaminase elevations are common. Discontinue if hepatitis or symptomatic elevation develops. - Blood Pressure (orthostatic)Each visit; lying and standing during titration
RoutineOrthostatic hypotension most dangerous during initiation and re-initiation after missed doses.
Contraindications & Cautions for Clozapine
Absolute Contraindications
- Known serious hypersensitivity to clozapine or any excipient (e.g. photosensitivity, vasculitis, erythema multiforme, Stevens-Johnson syndrome).
Relative Contraindications (Specialist Input Recommended)
- Active uncontrolled seizure disorder — clozapine lowers seizure threshold in a dose-dependent manner (~5% cumulative seizure incidence at 1 year).
- Uncontrolled narrow-angle glaucoma — potent anticholinergic effects.
- Active severe hepatic disease — impaired clozapine metabolism; hepatotoxicity risk.
- Paralytic ileus or bowel obstruction — anticholinergic GI hypomotility may worsen condition.
- Significant cardiac disease (decompensated heart failure, recent MI) — orthostatic hypotension and myocarditis risk.
Use with Caution
- History of seizures or conditions lowering seizure threshold
- Cardiovascular or cerebrovascular disease
- Prostatic hypertrophy or urinary retention
- Diabetes or metabolic syndrome risk factors
- Conditions predisposing to hypotension (dehydration, antihypertensive use)
- Elderly patients (increased sensitivity to orthostatic, anticholinergic, and metabolic effects)
- CYP2D6 poor metabolisers (may accumulate clozapine)
Clozapine can cause severe neutropenia (ANC <500/µL), leading to serious and fatal infections. Baseline ANC must be ≥1500/µL (general) or ≥1000/µL (BEN) before initiation. Regular ANC monitoring is recommended throughout treatment.
2. Orthostatic Hypotension, Bradycardia, SyncopeCan occur with the first dose, at doses as low as 12.5 mg, or when restarting after even brief interruption. Cardiac arrest has occurred. Initiate at 12.5 mg; titrate slowly; use divided doses.
3. SeizuresDose-related. Cumulative incidence approximately 5% at one year. Initiate at low dose, titrate gradually, use divided dosing.
4. Myocarditis, Pericarditis, CardiomyopathyFatal myocarditis and cardiomyopathy have occurred. Discontinue and obtain cardiac evaluation upon suspicion. Generally do not rechallenge.
5. Increased Mortality in Elderly with Dementia-Related PsychosisClozapine is not approved for use in patients with dementia-related psychosis.
Patient Counselling for Clozapine
Purpose of Therapy
Clozapine is prescribed because other antipsychotic medications have not adequately controlled symptoms, or because there is a specific need to reduce the risk of suicidal behaviour. Clozapine is the most effective antipsychotic available for treatment-resistant illness, and studies show it reduces overall mortality compared to other treatments. It requires careful monitoring but can be life-changing when other options have failed.
How to Take
Take clozapine exactly as prescribed, usually in divided doses (morning and evening). It can be taken with or without food. Do not stop taking clozapine suddenly — abrupt discontinuation can cause uncomfortable withdrawal symptoms and rapid return of psychosis. If you miss doses, contact your prescriber before resuming, as the dose may need to be reduced and re-titrated.
Sources
- CLOZARIL (clozapine) Tablets. Full Prescribing Information. HLS Therapeutics (USA), Inc. Revised 01/2025. FDA LabelPrimary source for all dosing, boxed warnings, ANC monitoring algorithms, adverse reactions, and drug interactions.
- FDA Drug Safety Communication: FDA removes REMS programme for clozapine. June 13, 2025. FDA.govOfficial FDA communication on REMS removal; confirms ANC monitoring still recommended per PI.
- Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789-796. DOILandmark trial establishing clozapine superiority over chlorpromazine in treatment-resistant schizophrenia.
- Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60(1):82-91. DOIInterSePT trial demonstrating clozapine superiority over olanzapine in reducing suicidal behaviour.
- Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet. 2009;374(9690):620-627. DOIFinnish cohort study showing clozapine is associated with the lowest overall mortality of all antipsychotics.
- Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia. Am J Psychiatry. 2020;177(9):868-872. DOIAPA guideline recommending clozapine for treatment-resistant schizophrenia and patients at substantial risk of suicide.
- Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216-229. DOIInternational consensus on defining treatment-resistant schizophrenia and the role of clozapine.
- Meltzer HY. An overview of the mechanism of action of clozapine. J Clin Psychiatry. 1994;55 Suppl B:47-52. PubMedSeminal review of clozapine’s multi-receptor pharmacology including D4, 5-HT2A, and low D2 occupancy.
- Remington G, Agid O, Foussias G, et al. Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold? Psychopharmacology (Berl). 2013;225(3):505-518. DOIEvidence review supporting the 350 ng/mL therapeutic threshold and the clinical value of TDM for clozapine.
- Couchman L, Morgan PE, Spencer EP, Flanagan RJ. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors. Ther Drug Monit. 2010;32(4):438-447. DOILarge TDM study characterising the relationship between dose, smoking, sex, and clozapine plasma concentrations.
- Reeves D, Shawon MSR, Gee SH, et al. A population pharmacokinetic model to guide clozapine dose selection, based on age, sex, ethnicity, body weight and smoking status. Br J Clin Pharmacol. 2024;90(1):259-272. DOIPopulation PK model incorporating demographic and environmental covariates for individualised clozapine dosing.
- Every-Palmer S, Ellis PM, Nowitz M, et al. The Porirua Protocol in the treatment of clozapine-induced gastrointestinal hypomotility and target monitoring with radiopaque markers. Ther Adv Psychopharmacol. 2017;7(1):75-81. DOIProtocol for objective assessment and management of clozapine-induced GI hypomotility using transit markers.